|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1341476595 |
| 003 |
OCoLC |
| 005 |
20231120010700.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
220822s2022 ne o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d OCLCF
|d UKMGB
|d UKAHL
|d OCLCQ
|d OCLCO
|d TEU
|
| 015 |
|
|
|a GBC2K3839
|2 bnb
|
| 016 |
7 |
|
|a 020743436
|2 Uk
|
| 020 |
|
|
|a 9780323859318
|q (electronic bk.)
|
| 020 |
|
|
|a 0323859313
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128244081
|
| 020 |
|
|
|z 0128244089
|
| 035 |
|
|
|a (OCoLC)1341476595
|
| 050 |
|
4 |
|a RM301.25
|
| 082 |
0 |
4 |
|a 615.19
|2 23
|
| 245 |
0 |
0 |
|a Applications of nanotechnology in drug delivery and delivery /
|c edited by Chukwuebuka Egbuna, Mihnea-Alexandru Gman and Jaison Jeevanandam.
|
| 260 |
|
|
|a Amsterdam :
|b Elsevier,
|c 2022.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|2 rdacontent
|
| 337 |
|
|
|a computer
|2 rdamedia
|
| 338 |
|
|
|a online resource
|2 rdacarrier
|
| 490 |
0 |
|
|a Drug discovery update
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Front Cover -- Applications of Nanotechnology in Drug Discovery and Delivery -- Copyright Page -- Contents -- List of contributors -- 1 Fundamentals, Trends and Advances in Nanotechnology -- 1 Roles of nanoparticles in drug discovery and delivery -- 1.1 Introduction -- 1.2 Types of nanoparticles -- 1.2.1 Lipid nanoparticles -- 1.2.2 Polymer-based nanoparticles -- 1.2.3 Inorganic component-based nanoparticles -- 1.3 Application of nanoparticles -- 1.3.1 Drug release profile -- 1.3.2 Gene delivery -- 1.3.3 Pulmonary delivery -- 1.3.4 Antimicrobial delivery -- 1.3.5 Brain targeting -- 1.3.6 Pharmacokinetics and biodistribution -- 1.3.7 Mucoadhesive delivery -- 1.3.8 Skin delivery -- 1.3.9 Macrophage uptake -- 1.3.10 Nanotheranostics -- 1.4 Summary and conclusion -- References -- 2 Nanoencapsulation of nutraceuticals and dietary supplements for effective delivery -- 2.1 Introduction -- 2.2 Nutraceuticals -- 2.3 Nanoencapsulation of nutraceuticals and dietary supplements -- 2.4 Nanoencapsulation techniques for nutraceuticals -- 2.4.1 Emulsification technique -- 2.4.2 Nanoprecipitation technique -- 2.4.3 Coacervation technique -- 2.5 Encapsulated nutraceuticals for drug delivery -- 2.5.1 Nanoemulsions -- 2.5.2 Polymeric nanoparticles -- 2.5.3 Magnetic nanoparticles -- 2.5.4 Nanoliposomes -- 2.5.5 Nanophytosomes -- 2.6 Conclusion -- Abbreviations -- References -- 3 Nanoformulation of antioxidant supplements -- 3.1 Introduction -- 3.2 Nanoformulations methods -- 3.2.1 Emulsion solvent evaporation method -- 3.2.2 Solvent displacement method -- 3.2.3 Supercritical fluid technology -- 3.2.4 Template synthesis method -- 3.2.5 Chemical precipitation technique -- 3.2.6 Nanoprecipitation -- 3.3 Nanoformulations for antioxidants -- 3.3.1 Natural or plant-derived nanoantioxidants -- 3.3.1.1 Nanocurcumin -- 3.3.1.2 Nanoepigallocatechin-3-gallate.
|
| 505 |
8 |
|
|a 3.3.1.3 Nanogenistein -- 3.3.1.4 Nanoquercetin -- 3.3.1.5 Nanoresveratrol -- 3.3.1.6 Nanorosmarinic acid -- 3.3.2 Chemical and synthetic nanoantioxidants -- 3.3.2.1 Silica nanoparticles -- 3.3.2.2 Gold nanoparticles -- 3.3.2.3 Silver nanoparticles -- 3.3.2.4 Iron oxide magnetic nanoparticles -- 3.3.2.5 Cerium oxide nanoparticles -- 3.3.2.6 Dual nanoantioxidant -- 3.3.2.7 Polymeric nanoantioxidant -- 3.3.2.8 Metal nanoantioxidants -- 3.4 Antioxidants in nanomedicine -- 3.4.1 Vitamin C -- 3.4.2 Vitamin E -- 3.4.3 Beta-carotene -- 3.4.4 Selenium -- 3.5 Advantages and disadvantages of nanofomulation of antioxidant supplements -- 3.6 Future perspective and conclusion -- Abbreviations -- References -- 4 Nanophytomedicines: nature to medicines -- 4.1 Introduction -- 4.2 Nanophytomedicines -- 4.3 Therapeutic potentials of nanophytomedicine -- 4.4 Nanophytomedicines with improved target binding ability -- 4.5 Nanophytomedicines and their oral bioavailability -- 4.6 Nanophytomedicine with improved safety -- 4.7 Toxicity of nanophytomedicine -- 4.8 Regulatory aspects and ethical issues associated with nanophytomedicine -- 4.9 Challenges encountered in nanophytomedicine -- 4.10 Current progress and future prospects -- 4.11 Conclusion -- References -- 5 Characterization of nanoparticles: methods and techniques -- 5.1 Introduction -- 5.2 Differential scanning calorimetry -- 5.3 Fourier transform infrared spectroscopy -- 5.4 Scanning electron microscopy -- 5.5 Transmission electron microscopy -- 5.6 X-Ray diffraction -- 5.7 Encapsulation efficiency, drug-loading capacity, and percentage of recovery -- 5.8 Topical nanoparticle strategies -- 5.9 Drug release studies of nanoparticles -- 5.9.1 Drug release study of nanoparticles for oral dosage forms -- 5.9.2 Drug release study of nanoparticles for topical dosage forms -- 5.10 Solubility of nanoparticles.
|
| 505 |
8 |
|
|a 5.11 Toxicity effects of nanoparticles -- 5.11.1 In vitro toxicity effect -- 5.11.1.1 In vivo toxicity effect for topical administration of nanoparticles -- 5.11.1.2 In vivo toxicity effects for oral administration of nanoparticles -- 5.12 Stability enhancement of nanoparticles -- 5.13 Future projection and conclusion -- References -- 2 Nanopharmaceutical Applications In Clinical Practice -- 6 Applications of nanotechnology in pharmaceutical products -- 6.1 Introduction -- 6.2 Comparison of traditional and nanodrug delivery -- 6.2.1 Essentials of drug delivery system -- 6.2.2 Conventional versus novel drug delivery system -- 6.2.3 Carrier-based drug delivery system -- 6.2.4 Nanodrug delivery system as a carrier-based drug delivery system -- 6.3 Pharmaceutical products through nanotechnology -- 6.3.1 Classification of nanopharmaceutical products -- 6.3.1.1 Nanomaterials -- 6.3.1.2 Nanodevices -- 6.4 Applications of nanotechnology in pharmaceutical processes -- 6.4.1 Drug delivery -- 6.4.2 Gene therapy -- 6.4.3 Medical diagnosis -- 6.4.4 Drug discovery -- 6.4.5 Other novel applications -- 6.5 Challenges in nanotechnology-based drug delivery system -- 6.6 Conclusion and future perspectives -- References -- 7 Advances in nanotechnology for drug discovery and design -- 7.1 Introduction -- 7.2 Nanomaterials, nanotechnology, and nanobiotechnology -- 7.2.1 Nanomaterials -- 7.2.2 Nanotechnology -- 7.2.3 Nanobiotechnology -- 7.3 Role of nanotechnology and nanobiotechnology in biomedicine -- 7.3.1 Biopolymer nanoparticles -- 7.3.2 Protein and polysaccharide nanoparticles -- 7.3.3 Liposomes -- 7.3.4 Polymeric micelles -- 7.3.5 Nanocrystals -- 7.3.6 Quantum dots -- 7.3.7 Dendrimers -- 7.3.8 Metallic nanoparticles -- 7.4 Hurdles and challenges -- 7.5 Future perspectives -- 7.6 Summary and conclusion -- References -- Further reading.
|
| 505 |
8 |
|
|a 8 Nanomedicine for diabetes mellitus management -- 8.1 Introduction -- 8.2 Type 1 diabetes mellitus and nanomedicine -- 8.3 Type 2 diabetes mellitus and nanomedicine -- 8.4 Insulin delivery and nanotechnology -- 8.4.1 Polymeric nanoparticles -- 8.4.2 Ceramic nanoparticles -- 8.4.3 Polymeric micelles -- 8.4.4 Dendrimers -- 8.4.5 Liposomes -- 8.4.6 Other nanoparticles -- 8.5 Nanopumps -- 8.6 Insulin delivery via inhalation -- 8.7 Transplanted pancreatic islets nanoencapsulation -- 8.8 Biological microelectromechanical systems for insulin delivery -- 8.9 Nanotechnology in noninsulin remedy -- 8.9.1 Artificial pancreas -- 8.9.2 Nanopore immunoisolation tools -- 8.9.3 Nanorobotics -- 8.10 Nanotechnology applications in the management of diabetes-related complications -- 8.10.1 Nanotechnology in diabetic retinopathy -- 8.10.2 Nanotechnology in diabetes-induced foot ulcers -- 8.10.3 Nanotechnology in other diabetes-associated complications -- 8.11 Advantages of using nanotechnology in diabetes mellitus management -- 8.12 Limitations in using nanotechnology in diabetes mellitus management -- 8.13 Conclusion -- References -- 9 Nanotechnological application of peptide- and protein-based therapeutics -- 9.1 Introduction -- 9.2 Benefits of peptide and protein therapeutics in biomedicine -- 9.3 Challenges with peptide- and protein-based therapeutics -- 9.4 Excipients used in synthesis of protein and peptide nanoparticles -- 9.4.1 Gliadin -- 9.4.2 Milk protein -- 9.4.3 Legumin -- 9.4.4 Elastin -- 9.4.5 Albumin -- 9.4.6 Gelatin -- 9.4.7 Zein -- 9.4.8 Soy protein -- 9.5 Therapeutic and diagnostic applications of protein-based therapeutics nanomaterials -- 9.5.1 Therapeutic application -- 9.5.1.1 Ocular disease applications -- 9.5.1.2 Application in cancer treatment -- 9.5.1.3 Applications of nanoparticles of protein-based therapeutics in treatment of other diseases.
|
| 505 |
8 |
|
|a 9.5.2 Diagnostic applications -- 9.5.2.1 Magnetic nanoparticles -- 9.5.2.2 Carbon nanotubes and gold nanoparticles -- 9.5.2.3 Other diagnostics using protein-based therapeutic nanoparticles -- 9.6 Improving stability using protein-based therapeutics nanoparticles -- 9.6.1 Physical stability enhancement -- 9.6.2 Biological stability improvement -- 9.7 Evaluation parameters and formulation techniques for protein/peptide nanoparticles -- 9.7.1 Emulsification method -- 9.7.2 Desolvation method -- 9.7.3 Electrospray method -- 9.7.4 Complex coacervation method -- 9.8 Biomedical applications of nanoparticles of proteins and peptides -- 9.8.1 Routes -- 9.8.1.1 Oral route -- 9.8.1.2 Blood-brain barrier routes -- 9.8.1.3 Nasal route -- 9.8.1.4 Pulmonary route -- 9.8.2 Antibiotics -- 9.8.3 Delivery of nonviral gene -- 9.8.4 Immunological adjuvant -- 9.8.5 Treatment of diseases -- 9.9 Concerns about peptide- and protein-based nanoparticles -- 9.10 Future prospects -- 9.11 Conclusion -- Abbreviations -- References -- 10 Nanodrug delivery systems in cancer therapy -- 10.1 Introduction -- 10.2 Currently available conventional cancer therapy -- 10.3 Drug delivery systems -- 10.4 Drug carriers -- 10.4.1 Types of drug carriers -- 10.4.1.1 Microspheres -- 10.4.1.2 Polymeric micelles -- 10.4.1.3 Liposomes -- 10.4.1.4 Nanodiamonds -- 10.4.1.5 Nanofibers -- 10.5 Protein nanoparticles -- 10.6 Anticancer nanoparticle drugs -- 10.7 Application of nanodrug delivery systems -- 10.8 Drawbacks of using nanodrug delivery -- 10.9 Conclusion and future perspectives -- References -- 11 Nanotechnology interventions in neuroscience: current perspectives and strategies -- 11.1 Introduction -- 11.2 Nanotechnology in neuroimaging -- 11.3 Nanotechnology in neurodiagnostic -- 11.4 Nanotechnology in neurological devices.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
0 |
|a Drug delivery systems.
|
| 650 |
|
0 |
|a Nanotechnology.
|
| 650 |
|
2 |
|a Drug Delivery Systems
|0 (DNLM)D016503
|
| 650 |
|
2 |
|a Nanotechnology
|0 (DNLM)D036103
|
| 650 |
|
6 |
|a M�edicaments
|x D�eveloppement.
|0 (CaQQLa)201-0306620
|
| 650 |
|
6 |
|a Syst�emes d'administration de m�edicaments.
|0 (CaQQLa)000260397
|
| 650 |
|
6 |
|a Nanotechnologie.
|0 (CaQQLa)201-0225435
|
| 650 |
|
7 |
|a Drug delivery systems
|2 fast
|0 (OCoLC)fst00898667
|
| 650 |
|
7 |
|a Drug development
|2 fast
|0 (OCoLC)fst00898670
|
| 650 |
|
7 |
|a Nanotechnology
|2 fast
|0 (OCoLC)fst01032639
|
| 700 |
1 |
|
|a Egbuna, Chukwuebuka.
|
| 776 |
0 |
8 |
|c Original
|z 0128244089
|z 9780128244081
|w (OCoLC)1257401554
|
| 776 |
0 |
8 |
|i Print version:
|t APPLICATIONS OF NANOTECHNOLOGY IN DRUG DISCOVERY AND DELIVERY.
|d [S.l.] : ELSEVIER, 2022
|z 0128244089
|w (OCoLC)1257401554
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128244081
|z Texto completo
|
